Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants.

Kiguba R, Karamagi C, Waako P, Ndagije HB, Bird SM.

BMJ Open. 2014 Nov 24;4(11):e005869. doi: 10.1136/bmjopen-2014-005869.

2.

Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans.

Nanzigu S, Kiguba R, Kabanda J, Mukonzo JK, Waako P, Kityo C, Makumbi F.

HIV AIDS (Auckl). 2013 Dec 6;5:309-19. doi: 10.2147/HIV.S50614. eCollection 2013.

3.

Assessing the quality of informed consent in a resource-limited setting: a cross-sectional study.

Kiguba R, Kutyabami P, Kiwuwa S, Katabira E, Sewankambo NK.

BMC Med Ethics. 2012 Aug 21;13:21. doi: 10.1186/1472-6939-13-21.

4.

Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.

Nanzigu S, Eriksen J, Makumbi F, Lanke S, Mahindi M, Kiguba R, Beck O, Ma Q, Morse GD, Gustafsson LL, Waako P.

HIV Med. 2012 Apr;13(4):193-201. doi: 10.1111/j.1468-1293.2011.00952.x. Epub 2011 Nov 22.

PMID:
22107359
5.

Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.

Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, Schlech WF, Katabira ET.

Afr Health Sci. 2011 Mar;11(1):16-23.

6.

Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors.

Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, Katabira E.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):218-23.

PMID:
17438478
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk